The Presence of Circulating Clonal CD19⁺ Cells in Multiple Myeloma

References

• Hansen O. P., Galton D. A.G. Classification and prognostic variables in myelomatosis. Scandinavian Journal of Haematology 1985; 35: 10–19
   PubMedGoogle Scholar
• Barlogie B., Jagannath S., Epstein J., Munshi N., Siegel D., Desikan K. R., Feinman R., Hsu R-L., Von Bremen K., Tricot G. Biology and therapy of multiple myeloma (1996). Seminars in Hematology 1997; 34((Suppl. 1))67–72
   PubMed Web of Science ®Google Scholar
• Attal M., Harousseau J. L., Stoppa A. M., Sotto J. J., Fuzibet J. G., Rossi J. F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Szczepek A. J., Belch A. R. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 1997; 90: 3751–3759
   PubMed Web of Science ®Google Scholar
• Szczepek A. J., Bergsagel P. L., Axelsson L., Brown C. B., Belch A. R., Pilarski L. M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997; 89: 1824–1833
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Smith A. M., Szczepek A., Mant M. J., Belch A. R., Pilarski L. M. Multiple myeloma, clonotypic B lymphocytes are detectable among CD 19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Masellis-Smith A., Szczepek A., Mant M. J., Belch A. R. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leukemia and Lymphoma 1996; 22: 375–383
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. R. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Leukemia and Lymphoma 1995; 17: 367–374
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. R. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Jensen G. S. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematology Oncology Clinical North America 1992; 6: 297–322
   PubMed Web of Science ®Google Scholar
• Szczepek A. J., Seeberger K., Wizniak J., Mant M. J., Belch A. J., Pilarski L. M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologues bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844–2855
   PubMed Web of Science ®Google Scholar
• Kay N. E., Leong T., Kyle R. A., Greipp P., Billadeau D., Van N. B., Bone N., Oken M. M. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the eastern cooperative oncology group phase III E9486 clinical trial. Blood 1997; 90: 340–345
   PubMed Web of Science ®Google Scholar
• Chen B. J., Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 1996; 87: 1972–1976
   PubMed Web of Science ®Google Scholar
• Ocqueteau M., Orfao A., Almeida J., Blade J., Gonzalez M., Garcia-Sanz R., Lopez-Berges C., Moro M. J., Hernandez J., Escribano L., Caballero D., Rozman M., San M. J. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. American Journal of Pathology 1998; 152: 1655–1665
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G.J., San Miguel J. F. Cell surface markers in multiple myeloma. Mayo Clinics Proceedings 1994; 69: 684–690
   PubMed Web of Science ®Google Scholar
• Harada H., Kawano M. M., Huang N., Harada Y., Iwato K., Tanabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658–2663
   PubMed Web of Science ®Google Scholar
• Ocqueteau M., Orfao A., Garcia-Sanz R., Almeida J., Gonzalez M., San M. J. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. British Journal of Haematology 1996; 95: 489–493
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C., Batailie R., Robillard N., Harousseau J. L., Rapp M. J., Juge-Morineau N., Wijdenes J., Amiot M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597–2603
   PubMed Web of Science ®Google Scholar
• Bakkus M. H., Van R. I., De G. C., Van C. B., Thielemans K. 'The clonogenic precursor cell in multiple myeloma. Leukemia and Lymphoma 1995; 18: 221–229
   PubMed Web of Science ®Google Scholar
• Deane M., Norton J. D. Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. British Journal of Haematology 1990; 74: 251–256
   PubMed Web of Science ®Google Scholar
• Deane M., Norton J. D. Immunoglobulin gene fingerprinting: an approach to analysis of B lymphoid clonality in lymphoproliferative disorders. British Journal of Haematology 1991; 77: 274–281
   PubMed Web of Science ®Google Scholar
• Bird J. M., Russell N. H., Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplantation 1993; 12: 651–654
   PubMed Web of Science ®Google Scholar
• Bird J. M., Bloxham D., Samson D., Marcus R. E., Russell N. H., Kelsey S. M., Newland A. C., Apperley J. F. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. British Journal of Haematology 1994; 88: 110–116
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Omede P., Astolfi M., Boccadoro M., Dalla-Favera R., Pileri A. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 1993; 7: 1879–1882
   PubMed Web of Science ®Google Scholar
• Billadeau D., Quam L., Thomas W., Kay N., Greipp P., Kyle R., Oken M. M., Van N. B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Astolfi M., Ladetto M., Tarella C., Boccadoro M., Pileri A. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596–1602
   PubMed Web of Science ®Google Scholar
• Henry J. M., Sykes P. J., Brisco M. J., To L. B., Juttner C. A., Morley A. A. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. British Journal of Haematology 1996; 92: 614–619
   PubMed Web of Science ®Google Scholar
• Bakkus M. H., Heirman C., Van R. I., Van C. B., Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335
   PubMed Web of Science ®Google Scholar
• Ralph Q. M., Brisco M., Joshua D. E., Brown R., Gibson J., Morley A. A. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain. Blood 1993; 82: 202–206
   PubMed Web of Science ®Google Scholar
• Vescio R. A., Cao J., Hong C. H., Lee J. C., Wu C. H., Der D. M., Wu V., Newman R., Lichtenstein A. K., Berenson J. R. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. Journal of Immunology 1995; 155: 2487–2497
   PubMed Web of Science ®Google Scholar
• Biggs D. D., Kraj P., Goldman J., Jefferies L., Carchidi C., Anderson K., Silberstein L. E. Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma. Clinical and Diagnostic Laboratory Immunology 1995; 2: 44–52
   PubMedGoogle Scholar
• Rasmussen T., Honore L., Johnsen H. E. Identification and characterization of malignant cells using RT-PCR on single flowsorted cells. Medical Oncology 1998; 15: 96–102
   PubMed Web of Science ®Google Scholar
• Cao J., Vescio R. A., Rettig M. B., Hong C. H., Kim A., Lee J. C., Lichtenstein A. K., Berenson J. R. A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers. Leukemia 1995; 9: 1948–1953
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Kastrup J., Knudsen L. M., Johnsen H. E. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. British Journal of Haematology 1999; 105: 265–267
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Jensen L., Honore L., Andersen H., Johnsen H. E. Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. British Journal of Haematology 1999; 107: 818–824
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Jensen L., Johnsen H. E. The clonal hierachy in multiple myeloma. Acta Oncologica 2001; 39: 765–770
   Web of Science ®Google Scholar
• Terstappen L. W., Johnsen S., Segers-Nolten I. M., Loken M. R. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990; 76: 1739–1747
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Kimlinger T. K., Ahmann G. J., Katzmann J. A., Greipp PR. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996; 26: 113–120
   PubMedGoogle Scholar
• Witzig T. E., Gertz M. A., Lust J. A., Kyle R. A., O'Fallon W. M., Greipp P. R. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996; 88: 1780–1787
   PubMed Web of Science ®Google Scholar
• Rawstron A., Owen R. G., Davies F. E., Johnson R. J., Jones R. A., Richards S. J., Evans P. A., Child J. A., Smith G. M., Jack A. S., Morgan G. J. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British Journal of Haematology 1997; 97: 46–55
   PubMed Web of Science ®Google Scholar
• Mahmoud M. S., Fujii R., Ishikawa H., Kawano M. M. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999; 94: 3551–3558
   PubMed Web of Science ®Google Scholar
• Hallek M., Leif B. P., Anderson K. C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21
   PubMed Web of Science ®Google Scholar
• Billadeau D., Ahmann G., Greipp P., Van N. B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine 1993; 178: 1023–1031
   PubMed Web of Science ®Google Scholar
• Corradini P., Boccadoro M., Voena C., Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas. Journal of Experimental Medicine 1993; 178: 1091–1096
   PubMed Web of Science ®Google Scholar
• Bakkus M. H., Van R. I., Van C. B., Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. British Journal of Haematology 1994; 87: 68–74
   PubMed Web of Science ®Google Scholar
• Guikema J. E., Vellenga E., Veeneman J. M., Hovenga S., Bakkus M. H., Klip H., Bos N. A. Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. British Journal of Haematology 1999; 104: 748–754
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Chesi M., Nardini E., Brents L. A., Kirby S. L., Kuchi W. M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings National Academy Sciences United States America 1996; 93: 13931–13936
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H., Li J. Y., Morineau N., Facon T., Brigaudeau C., Harousseau J. L., Grosbois B., Bataille R. Monosomy 13 is associated with the transitin of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 1999; 94: 2586–2589
   Google Scholar
• Rasmussen T., Poulsen T. S., Honore L., Johnsen H. E. Quantitation of minimal residual disease in multiple myeloma using an allele specific real-time PCR assay. Experimental Hematology 2000; 28: 1039–1045
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Jensen L., Honore L., Johnsen H. E. Frequency and kinetics of polyclonal and clonal B-cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000; 96: 4357–4359
   PubMed Web of Science ®Google Scholar
• Billadeau D., Prosper F., Verfaillie C., Weisdorf D., Van N. B. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement. Leukemia 1997; 11: 1565–1570
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Johnsen H. E. Controversies surrounding the circulating clonotypic B-lymphocytes in multiple myeloma. Blood 2001
   Web of Science ®Google Scholar
• Rottenburger C., Kiel K., Bösing T., Cremer F. W. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. British Journal of Haematology 1999; 106: 545–552
   PubMed Web of Science ®Google Scholar
• Yaccoby S., Epstein J. Primary myeloma cells growing in SCGD-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908–2913
   PubMed Web of Science ®Google Scholar
• Yaccoby S., Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576–3582
   PubMed Web of Science ®Google Scholar
• Sahota S., Garand R., Mahroof R., Smith A., Juge-Morineau N., Stevenson F. K., Bataille R. VH gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Blood 1999; 94: 1070–1076
   PubMed Web of Science ®Google Scholar
• Mitterer M., Odunch F., Lanthaler A. J., Drexler E., Amaddu G., Fabris P., Emmerich B., Coser P., Straka C. The relationship between monoclonal myeloma precusor B cells in the peripheral blood stem cell harvest and the clinical response of multiple myeloma patients. British Journal of Haematology 1999; 106: 737–741
   PubMed Web of Science ®Google Scholar
• Osterborg A., Yi Q., Henriksson L., Fagerberg J., Bergenbrant S., Jeddi-Tehrani M., Ruden U., Lefvert A. K., Holm G, Mellstedt H. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 1998; 91: 2459–2466
   PubMed Web of Science ®Google Scholar
• Rasmussen T., Jensen L., Johnsen H. E. Levels of circulating CD19+ cells in patients with multiple myeloma. Blood 2000; 95: 4020–4021
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Brown R. D., Luo X. F., Gibson J. Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization. Blood 1996; 88: 1125
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Giannakopoulos N. V., Szczepek A., Masellis-Smith A., Mant M. J., Belch A. J. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clinical Cancer Research 2000; 6: 585–596
   PubMed Web of Science ®Google Scholar
• Pilarski L. M. Circulating CD19+ blood cell levels in myeloma. Blood 1995; 86: 4001
   PubMed Web of Science ®Google Scholar
• Takishita M., Kosaka M., Goto T., Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. British Journal of Haematology 1994; 87: 735–742
   PubMed Web of Science ®Google Scholar
• Vescio R. A., Hong C. H., Cao J., Kim A., Schiller G. J., Lichtenstein A. K., Berenson R. J., Berenson J. R. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283–3290
   PubMed Web of Science ®Google Scholar
• Cremer F. W., Kiel K., Sucker C., Wacker J., Atzberger A., Haas R., Goldschmidt H., Moos M. A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells. Leukemia 1997; 11(5)S41-S46
   PubMedGoogle Scholar
• Kimlinger T., Witzig T. E. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplantation 1997; 19: 553–556
   PubMed Web of Science ®Google Scholar